Folfiri As Second-Line (2l) Treatment Of Metastatic Gastric Cancer (Mgc) In Clinical Practice: Efficacy, Safety, And Prognostic Factors.

e15053 Background: There is no standard treatment of 2L for mGC. Irinotecan has been shown to increase overall survival (OS) in this setting. FOLFIRI is an active and well-tolerated regimen which has previously been tested in phase II studies in both first-line (1L) and 2L. Methods: Retrospective study of patients (pts) with mGC who were treated in 2L with FOLFIRI (Irinotecan 180mg/m2 d1, Leucovorin 400mg/m2 and 5FU 400mg/m2 d1, followed 5FU 2400mg/m2in a 46h continuous infusion, every 2 weeks). We assessed response rate, clinical benefit rate (CBR), progression-free survival (PFS), OS and toxicity. Univariate analysis was performed to correlate the clinicopathological characteristics with PFS and OS. Results: 66 pts were included. Median age: 65y. 80% of pts had ECOG ≤1. Number of metastatic sites (NMS): 1 (41%), ≥2 (59%). Most common regimens in 1L: TPF (30%), CDDP-Capecitabine (30%) and CDDP-5FU (26%). Median of number cycles: 7. 55 pts were evaluable for response: complete response 4%, partial respons...